Reference health
RTS,S/AS01 vaccine (Mosquirix™): an overview
54/54 checkable references clean · checked 2026-07-26
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
4 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 54 checked references that resolve
resolves10.1371/journal.pone.0199172
Seasonal variations in Plasmodium falciparum parasite prevalence assessed by varying diagnostic tests in asymptomatic children in southern Ghana
resolves10.1186/1471-2458-11-S3-S14
Protective efficacy of malaria case management and intermittent preventive treatment for preventing malaria mortality in children: a systematic review for the Lives Saved Tool
resolves10.1086/589287
The Relationship between Age and the Manifestations of and Mortality Associated with Severe Malaria
resolves10.1056/NEJMoa1505819
Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine
resolves10.1097/00000441-197309000-00002
Immunization of man against sporozite-induced falciparum malaria
resolves10.1126/science.2409595
Rationale for Development of a Synthetic Vaccine Against
<i>Plasmodium falciparum</i>
Malaria
resolves10.1126/science.6204383
Structure of the Gene Encoding the Immunodominant Surface Antigen on the Sporozoite of the Human Malaria Parasite
<i>Plasmodium falciparum</i>
resolves10.1016/s0140-6736(87)90540-x
SAFETY AND EFFICACY OF A RECOMBINANT DNA PLASMODIUM FALCIPARUM SPOROZOITE VACCINE
resolves10.4269/ajtmh.2007.77.289
Two Decades of Commitment to Malaria Vaccine Development: GlaxoSmithKline Biologicals
resolves10.1016/j.vaccine.2015.09.061
RTS,S: Toward a first landmark on the Malaria Vaccine Technology Roadmap
resolves10.4269/ajtmh.1991.45.533
Phase I Clinical Trial of a Recombinant Malaria Vaccine Consisting of the Circumsporozoite Repeat Region of Plasmodium Falciparum Coupled to Hepatitis B Surface Antigen
resolves10.1056/NEJM199701093360202
A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine against<i>Plasmodium falciparum</i><i>Malaria</i>
resolves10.1016/j.vaccine.2007.05.005
A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naïve adults
resolves10.1086/600120
Randomized, Double‐Blind, Phase 2a Trial of Falciparum Malaria Vaccines RTS,S/AS01B and RTS,S/AS02A in Malaria‐Naive Adults: Safety, Efficacy, and Immunologic Associates of Protection
resolves10.1371/journal.pone.0006465
Evaluation of RTS,S/AS02A and RTS,S/AS01B in Adults in a High Malaria Transmission Area
resolves10.1056/NEJMoa0807381
Efficacy of RTS,S/AS01E Vaccine against Malaria in Children 5 to 17 Months of Age
resolves10.1371/journal.pone.0025786
Circumsporozoite-Specific T Cell Responses in Children Vaccinated with RTS,S/AS01E and Protection against P falciparum Clinical Malaria
resolves10.1371/journal.pone.0007302
Randomized Controlled Trial of RTS,S/AS02D and RTS,S/AS01E Malaria Candidate Vaccines Given According to Different Schedules in Ghanaian Children
resolves10.1371/journal.pone.0007611
A Randomized Trial Assessing the Safety and Immunogenicity of AS01 and AS02 Adjuvanted RTS,S Malaria Vaccine Candidates in Children in Gabon
resolves10.1086/656190
Evaluation of the Safety and Immunogenicity of the RTS,S/AS01<sub>E</sub>Malaria Candidate Vaccine When Integrated in the Expanded Program of Immunization
resolves10.1016/S0140-6736(15)60721-8
Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial
resolves10.1016/S1473-3099(16)30161-X
Safety and immunogenicity of RTS,S/AS01 malaria vaccine in infants and children with WHO stage 1 or 2 HIV disease: a randomised, double-blind, controlled trial
resolves10.1056/NEJMoa1515257
Seven-Year Efficacy of RTS,S/AS01 Malaria Vaccine among Young African Children
resolves10.1016/S0140-6736(15)00725-4
Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models
resolves10.1186/1475-2875-8-312
Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data
resolves10.1371/journal.pone.0025779
Impact of the RTS,S Malaria Vaccine Candidate on Naturally Acquired Antibody Responses to Multiple Asexual Blood Stage Antigens
resolves10.1016/j.vaccine.2011.03.041
Four year immunogenicity of the RTS,S/AS02A malaria vaccine in Mozambican children during a phase IIb trial
resolves10.1016/j.vaccine.2014.02.042
Duration of vaccine efficacy against malaria: 5th year of follow-up in children vaccinated with RTS,S/AS02 in Mozambique
resolves10.3389/fimmu.2017.01008
RTS,S/AS01E Malaria Vaccine Induces Memory and Polyfunctional T Cell Responses in a Pediatric African Phase III Trial
resolves10.1093/cid/cix429
Distinct Helper T Cell Type 1 and 2 Responses Associated With Malaria Protection and Risk in RTS,S/AS01E Vaccinees
resolves10.1186/s12916-018-1186-4
Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S/AS01E vaccination in African children
resolves10.1038/s41467-019-10195-z
Concentration and avidity of antibodies to different circumsporozoite epitopes correlate with RTS,S/AS01E malaria vaccine efficacy
resolves10.3389/fimmu.2019.00439
Differential Patterns of IgG Subclass Responses to Plasmodium falciparum Antigens in Relation to Malaria Protection and RTS,S Vaccination
resolves10.1186/s12916-019-1277-x
Induction and decay of functional complement-fixing antibodies by the RTS,S malaria vaccine in children, and a negative impact of malaria exposure
resolves10.1016/S1473-3099(15)00239-X
Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial
resolves10.1073/pnas.1621489114
Systems analysis of protective immune responses to RTS,S malaria vaccination in humans
resolves10.1371/journal.pone.0061395
The Relationship between RTS,S Vaccine-Induced Antibodies, CD4+ T Cell Responses and Protection against Plasmodium falciparum Infection
resolves10.4269/ajtmh.2003.68.97
PROTECTIVE EFFICACY OF THE RTS,S/AS02 PLASMODIUM FALCIPARUM MALARIA VACCINE IS NOT STRAIN SPECIFIC
resolves10.1371/journal.pctr.0010005
RTS,S/AS02A Malaria Vaccine Does Not Induce Parasite CSP T Cell Epitope Selection and Reduces Multiplicity of Infection
resolves10.1371/journal.pone.0007849
Impact of RTS,S/AS02A and RTS,S/AS01B on Genotypes of P. falciparum in Adults Participating in a Malaria Vaccine Clinical Trial
resolves10.1126/science.1211548
Live Attenuated Malaria Vaccine Designed to Protect Through Hepatic CD8
<sup>+</sup>
T Cell Immunity
resolves10.1038/nm.4110
Protection against malaria at 1 year and immune correlates following PfSPZ vaccination
resolves10.1126/science.1241800
Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite Vaccine
resolves10.1073/pnas.1615324114
Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection
resolves10.4269/ajtmh.17-1014
Safety, Immunogenicity, and Protective Efficacy against Controlled Human Malaria Infection of Plasmodium falciparum Sporozoite Vaccine in Tanzanian Adults
resolves10.1016/S1473-3099(17)30104-4
Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial
resolves10.1038/srep46621
Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine
resolves10.1093/infdis/jiw237
Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study
The 4 references without a DOI — listed, not checked
no DOI — not checkedWorld malaria report 2018. Geneva Switzerland: World Health Organization; 2018.
no DOI — not checkedTowards a global action plan for healthy lives and well-being for all. Geneva Switzerland: World Health Organization; 2018.
no DOI — not checkedAgency EM. Assessment report. Mosquirix. European medicines agency committee for medicinal products for human use 2015 23 July 2015. Report No.: EMA/CHMP/439337/2015.
no DOI — not checkedTables of malaria vaccine projects globally Geneva: World Health Organization. [accessed 2019 Jul 14]. https://www.who.int/immunization/research/development/Rainbow_tables/en/.
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-26 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1080/21645515.2019.1669415"><img src="https://citestamp.com/citestamped/10.1080/21645515.2019.1669415/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1080/21645515.2019.1669415)